论文信息 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study - 字舞流文

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

H. Goldschmidt | Shaji K. Kumar | T. Plesner | R. Orlowski | H. Nahi | N. Raje | P. Moreau | M. Macro | X. Leleu | S. Basu | L. Frenzel | T. Facon | M. O'Dwyer | A. Perrot | M. Tiab | C. Hulin | K. Weisel | N. Bahlis | R. Carson | C. Venner | H. Quach | H. Pei | M. Krevvata | F. Borgsten | Saad Z. Usmani